Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

Nature genetics | Dec 29, 2005

Somatic activating mutations in EGFR identify a subset of non-small cell lung cancer that respond to tyrosine kinase inhibitors. Acquisition of drug resistance is linked to a specific secondary somatic mutation, EGFR T790M. Here we describe a family with multiple cases of non-small cell lung cancer associated with germline transmission of this mutation. Four of six tumors analyzed showed a secondary somatic activating EGFR mutation, arising in cis with the germline EGFR mutation T790M. These observations implicate altered EGFR signaling in genetic susceptibility to lung cancer.

Pubmed ID: 16258541 RIS Download

Mesh terms: Antineoplastic Agents | Carcinoma, Non-Small-Cell Lung | Drug Resistance, Neoplasm | Female | Genetic Predisposition to Disease | Germ-Line Mutation | Humans | Lung Neoplasms | Male | Methionine | Middle Aged | Pedigree | Protein Kinase Inhibitors | Protein-Tyrosine Kinases | Receptor, Epidermal Growth Factor | Threonine

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

We have not found any resources mentioned in this publication.